ABSTRACT
Alzheimer’s disease (AD) is an illness that is set to create one of the world’s largest socioeconomic healthcare burdens in the coming decades. This underscores the urgency of seeking effective therapeutic interventions for patients with AD. Current therapeutic approaches for AD have been developed to alleviate its symptoms and to modify its disease course. Symptomatic treatment is directed at the cognitive, behavioral, and functional disability in AD. It is also considered from a global or more holistic view. Currently, four ChEIs (Tacrine, Donepezil, Rivastigmine, and Galantamine) are approved in most countries worldwide. In 1993, tacrine was the first ChEI approved for the treatment of AD. Its efficacy was demonstrated in trials of up to 6 months in patients with mild-to-moderate AD. Antioxidants have attracted attention as a potential therapy to reduce free radical damage resulting from increased oxidative stress.
